Please assess the completion status of the following clinical trial:

Trial Title: Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive adenocarcinoma of the breast, meeting any of the following criteria:~  * T4, NX, M0~ * Any T, N2-N3, M0~ * Inflammatory breast cancer (redness over at least one-third of the breast), M0~* No evidence of metastatic disease by chest x-ray, abdominal ultrasound or CT scan and bone scan~* Diagnosed within the past 8 weeks~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 16 and over~Sex~* Female~Menopausal status~* Not specified~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute granulocyte count at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic~* Bilirubin less than upper limit of normal (ULN)~* Must meet criteria for 1 of the following:~  * ALT and AST no greater than 1.5 times ULN AND alkaline phosphatase no greater than 2.5 times ULN~ * ALT and AST normal AND alkaline phosphatase no greater than 5 times ULN~Renal~* Creatinine no greater than 1.5 times ULN~Cardiovascular~* Resting LVEF normal by MUGA or echocardiogram~* No congestive heart failure~* No angina pectoris~* No myocardial infarction within the past year~* No uncontrolled hypertension~* No uncontrolled arrhythmias~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective non-hormonal contraception~* No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix~* No symptomatic peripheral neuropathy grade 2 or greater~* No active infection~* No history of significant neurological or psychiatric disorders, including dementia or seizures~* No peptic ulcer~* No unstable diabetes mellitus~* No contraindication to dexamethasone~* No known sensitivity to E. coli-derived or polyethylene glycol products~* Willing to undergo core biopsies once prior to registration and core biopsies at 2 other timepoints while on study~* Geographically accessible for treatment and follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior immunotherapy for breast cancer~Chemotherapy~* No prior chemotherapy for breast cancer~Endocrine therapy~* No prior hormonal therapy for breast cancer~* No concurrent corticosteroids except for premedication or hypersensitivity reaction~* No concurrent oral contraception~Radiotherapy~* No prior radiotherapy for breast cancer~Surgery~* No prior surgery for breast cancer other than biopsy~Other~* No prior systemic therapy for breast cancer~* No other concurrent investigational drugs or anticancer treatment~* No concurrent preventative IV antibiotics

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pegfilgrastim, docetaxel and epirubicin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete